Pacira BioSciences, Inc. (PCRX) NASDAQ
24.36
+1.01(+4.33%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
24.36
+1.01(+4.33%)
Currency In USD
| Previous Close | 23.35 |
| Open | 23.34 |
| Day High | 24.7 |
| Day Low | 22.87 |
| 52-Week High | 27.64 |
| 52-Week Low | 18.8 |
| Volume | 612,846 |
| Average Volume | 695,086 |
| Market Cap | 958.2M |
| PE | 187.38 |
| EPS | 0.13 |
| Moving Average 50 Days | 23.53 |
| Moving Average 200 Days | 23.72 |
| Change | 1.01 |
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
GlobeNewswire Inc.
Mar 04, 2026 1:00 PM GMT
BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will pa
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with osteoarthritis (OA) of the knee -- -- Data presented at the American Academy of Orthopedic Surgeons 20
Pacira to Report 2025 Financial Results on Thursday February 26, 2026
GlobeNewswire Inc.
Feb 12, 2026 9:01 PM GMT
BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will rep